Replies to post #20766 on Biotech Values

[RockRat]

Charlie and DrBio45,

Your comments on the Ambrisentan data are very interesting to me as someone who is checking out ENCY. DrBio wrote that patients with connective tissue disease were excluded form the ARIES trials. I do not see this in the protocol (ENCY's included for comaparison):

http://www.myogen.com/clinical/aries.php

http://www.encysive.com/clinical.html

So DrBio45, may I ask your source for this assertion?

And Charlie, ditto on the % of CT disease patients in the Thelin trial.

Do you guys have links or references where I can see these criteria & numbers?

I'd appreciate any help. And I'm looking forward to further dissection of the issue.

Thanks in Advance & Regards, RockRat